Drug-related problems in Parkinson's disease: The role of community pharmacists in primary care

International Journal of Clinical Pharmacy

Volumn 33, Issue 4, 2011, Pages 674-682

  Schröder, Sabrina ^a   Martus, Peter ^a   Odin, Per ^b,c   Schaefer, Marion ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Central Hospital   (Germany)

Author keywords

Community pharmacist; Drug related problems; Germany; Parkinson's disease; Pharmaceutical care

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BUDIPINE; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; INSULIN LISPRO; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; RASAGILINE; SIMVASTATIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ATTITUDE TO HEALTH; CLINICAL ASSESSMENT; COMMUNITY CARE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; FALLING; FEMALE; GERMANY; HAIR LOSS; HEMATOCHEZIA; HUMAN; HYPERTENSION; IDIOPATHIC DISEASE; INSULIN HYPOGLYCEMIA; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COUNSELING; PHARMACEUTICAL CARE; PHARMACIST ATTITUDE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; CHILD, PRESCHOOL; COMMUNITY PHARMACY SERVICES; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PHARMACISTS; PRIMARY HEALTH CARE; PROFESSIONAL ROLE;

EID: 80052407841     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-011-9526-x     Document Type: Article

References (38)

1. van Mil JWF. Proceedings of the international workings conference on outcomes measurement in pharmaceutical care 9. Pharmaceutical care network Europe (PCNE). Hilleroed, Denmark; 1999. p. 84. http://www.pcne.org/dokumenter/ PCNE%20scheme%20V4.00.pdf.
2. HL Lipton LA Bero JA Bird SJ McPhee 1992 The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. A randomized controlled trial Med Care 30 646 658 1614233 10.1097/00005650- 199207000-00006 1:STN:280:DyaK38zgvF2rtA%3D%3D
3. R Goldstein H Hulme J Willits 1998 Reviewing repeat prescribing-general practitioners and community pharmacists working together Int J Pharm Pract 6 60 66 10.1111/j.2042-7174.1998.tb00917.x (Pubitemid 28401179)
4. WP Munroe K Kunz C Dalmady-Israel L Potter WH Schonfeld 1997 Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting Clin Ther 19 113 123 9083713 10.1016/S0149-2918(97)80078-1 1:STN:280:DyaK2s3jslagtw%3D%3D (Pubitemid 27186443)
5. Scottish Department of Health Clinical Resource and Audit Group. Clinical pharmacy practice in primary care. Edinburgh: Scottish Office; 1998.
6. FR Ernst AJ Grizzle 2001 Drug-related morbidity and mortality: updating the cost-of-illness model J Am Pharm Assoc (Wash) 41 192 199 1:STN:280:DC%2BD3M3mvFOhtA%3D%3D
7. TK Gandhi DL Seger DW Bates 2000 Identifying drug safety issues: from research to practice Int J Qual Health Care 12 69 76 10733086 10.1093/intqhc/12.1.69 1:STN:280:DC%2BD3c7psFahtg%3D%3D (Pubitemid 30141024)
8. T Westerlund AB Almarsdottir A Melander 1999 Factors influencing the detection rate of drug-related problems in community pharmacy Pharm World Sci 21 245 250 10658231 10.1023/A:1008767406692 1:STN:280:DC%2BD3c7it1KqsA%3D%3D (Pubitemid 30041074)
9. JW van Mil MC Dudok van Heel M Boersma TF Tromp 2001 Interventions and documentation for drug-related problems in Dutch community pharmacies Am J Health Syst Pharm 58 1428 1431 11494789 (Pubitemid 32702407)
10. EI Paulino ML Bouvy MA Gastelurrutia M Guerreiro H Buurma 2004 Drug related problems identified by European community pharmacists in patients discharged from hospital Pharm World Sci 26 353 360 15683106
11. LT Westerlund BR Marklund WH Handl ME Thunberg P Allebeck 2001 Nonprescription drug-related problems and pharmacy interventions Ann Pharmacother 35 1343 1349 11724080 10.1345/aph.1A065 1:STN:280: DC%2BD3MnnslKjsw%3D%3D (Pubitemid 33042064)
12. MA Hubert R Mayer CE Müller 2002 Parkinson-Therapeutika. Teil II: Wirkstoff-Dossiers, Therapiekonzepte und pharmazeutische Betreuung Deutsche Apotheker Zeitung 39 62 71
13. JP Jameson GR Van Noord 2001 Pharmacotherapy consultation on polypharmacy patients in ambulatory care Ann Pharmacother 35 835 840 11485129 10.1345/aph.10259 1:STN:280:DC%2BD38%2FislCkug%3D%3D (Pubitemid 32678703)
14. G Cunningham TR Dodd DJ Grant ME McMurdo RM Richards 1997 Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment Age Ageing 26 375 382 9351482 10.1093/ageing/26.5.375 1:STN:280:DyaK1c%2FhtFyntQ%3D%3D (Pubitemid 27448382)
15. O Leoni E Martignoni M Cosentino D Michielotto D Calandrella R Zangaglia G Riboldazzi C Oria S Lecchini G Nappi G Frigo 2002 Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients Pharmacoepidemiol Drug Saf 11 149 157 11998540 10.1002/pds.682 (Pubitemid 34464336)
16. S Schröder YF Zöllner M Schaefer 2007 Drug related problems with Antiparkinsonian agents: consumer Internet reports versus published data Pharmacoepidemiol Drug Saf 16 1161 1166 17486665 10.1002/pds.1415 (Pubitemid 350020071)
17. Kooperationsvereinbarung zwischen der BEK und dem DAV. Vereinbarung zwischen der Barmer Ersatzkasse (BEK) und dem Deutschen Apothekerverband e.V. (DAV) zur Intensivierung der Kooperation bei der qualitätsorientierten Versorgung der Versicherten. 2003.
18. Schaefer M, Schulz M. Manuale zur Pharmazeutischen Betreuung. Band 1, Grundlagen der Pharmazeutischen Betreuung. Govi-Verlag; 2000. p 24.
19. Himstedt S, Kirchhoff G. Hausapotheke: Pharmazeutische Dienstleistung für die Patienten. Pharm Ztg. 2004. 19/44. http://www.pharmazeutische- zeitung.de/index.php?id=titel-19-2004 ; cited June 10 2005.
20. AJ Hughes SE Daniel L Kilford AJ Lees 1992 Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatr 55 181 184 1564476 10.1136/jnnp.55.3.181 1:STN:280:DyaK383is1Omsg%3D%3D
21. MM Hoehn MD Yahr 1967 Parkinsonism: onset, progression, and mortality Neurology 17 427 442 6067254 1:STN:280:DyaF2s7jvFSgsg%3D%3D
22. C Jenkinson R Fitzpatrick V Peto R Greenhall N Hyman 1997 The PDQ-8: development of a short form Parkinson's disease questionnaire Psychol Health 12 805 814 10.1080/08870449708406741
23. The EuroQol Group 1990 EuroQol: a new facility for the measurement of health-related quality of life Health Policy 16 199 208 10.1016/0168-8510(90) 90421-9
24. ATC-Index. Anatomisch-therapeutisch-chemische-Klassifikation mit Tagesdosen. Amtliche Fassung des ATC-Index mit DDD-Angaben für Deutschland im Jahr 2005. Status: 1 January 2005.
25. JWF van Mil T Westerlund KE Hersberger M Schaefer 2004 Drug-related problem classification systems Ann Pharmacother 38 859 867 15054145 10.1345/aph.1D182 (Pubitemid 38509068)
26. M Schaefer 2002 Discussing basic principles for a coding system of drug-related problems: the case of PI-Doc Pharm World Sci 24 120 127 12227243 10.1023/A:1019543029936 (Pubitemid 34951309)
27. Mattenklotz A. Vergleichende Validierung von zwei Klassifizierungssystemen für arzneimittelbezogene Probleme (PCNE und PiDoc). Master thesis, Charité-University Medicine Berlin; 2006.
28. KK Viktil SH Blix TA Moger A Reikvam 2006 Interview of patients by pharmacists contributes significantly to the identification of drug-related problems (DRPs) Pharmacoepidemiol Drug Saf 15 667 674 16598835 10.1002/pds.1238 (Pubitemid 44404666)
29. WHO Adverse Drug Reaction Dictionary. The WHO Adverse Reaction Terminology WHO-ART. Terminology for coding clinical information in relation to drug therapy (December 2005). http://www.umc-products.com/graphics/3149.pdf.
30. CIOMS Working Group IV. Benefit-risk balance for marketing drugs: safety signals. Geneva: CIOMS; 1998.
31. EMEA. Note for guidance on clinical safety data management: definitions and standards for expedited reporting. June 1995-CPMP/ICH/377/95. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500002749.pdf.
32. D Grosset A Antonini M Canesi G Pezzoli A Lees K Shaw E Cubo P Martinez-Martin O Rascol L Negre-Pages A Senard J Schwarz K Strecker H Reichmann A Storch M Löhle F Stocchi K Grosset 2009 Adherence to antiparkinson medication in a multicenter European study Mov Disord 24 826 832 19191340 10.1002/mds.22112
33. O Rascol P Payoux F Ory JJ Ferreira C Brefel-Courbon JL Montastruc 2003 Limitations of current Parkinson's disease therapy Ann Neurol 53 Suppl 3 3 15 10.1002/ana.10513 (Pubitemid 36368558)
34. O Rascol C Goetz W Koller W Poewe C Sampaio 2002 Treatment interventions for Parkinson's disease: an evidence based assessment Lancet 359 1589 1598 12047983 10.1016/S0140-6736(02)08520-3 (Pubitemid 34621128)
35. H Buurma PA De Smet HGM Leufkens AC Egberts 2004 Evaluation of the clinical value of pharmacists' modification of prescription errors Br J Clin Pharmacol 58 503 511 15521898 10.1111/j.1365-2125.2004.02181.x (Pubitemid 39540454)
36. KR Chaudhuri AH Schapira 2009 Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment Lancet Neurol 8 464 474 19375664 10.1016/S1474-4422(09)70068-7 1:CAS:528:DC%2BD1MXlsVajsb0%3D
37. MT Rupp 1992 Value of community pharmacists' interventions to correct prescribing errors Ann Pharmacother 26 1580 1584 1482816 1:STN:280: DyaK3s7ivFygtQ%3D%3D
38. KK Viktil HS Blix A Reikvam TA Moger BJ Hjemaas EK Walseth TF Vraalsen P Pretsch F Jorgensen 2004 Comparison of drug related-problems in different patient groups Ann Pharmacother 38 942 948 15069168 10.1345/aph.1D531 (Pubitemid 38657731)